Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul;13(13):1994-1997.
doi: 10.1111/1759-7714.14405. Epub 2022 May 26.

Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report

Pierre Magdelaine  1 , Adrien Costantini  1   2 , Lucie Fabre  3 , Etienne Giroux-Leprieur  1   2
Affiliations
Case Reports

Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report

Pierre Magdelaine et al. Thorac Cancer. 2022 Jul.

Abstract

Herein, we report a case of a 73-year-old female patient diagnosed with cT4N0M1a lung adenocarcinoma with KRAS G12C mutation, PDL1 < 1% and treated in fourth-line setting with gemcitabine after progression under nivolumab. After one infusion of gemcitabine, the patient presented with an acute worsening of general condition (performance status 4) with extensive skin lesions and fever, leading to hospitalization and diagnosis of acute generalized exanthematous pustulosis. Initial blood work revealed multiple organ failures with an important inflammatory syndrome. Patient state improved after intravenous hydration and local and systemic corticosteroids. The decision was made to stop systemic cancer treatment. Two months follow-up showed a remarkable response on all cancer localizations. Although immunotherapy is transforming cancer care, predicting response to immunotherapy remains challenging and resistant mechanisms remain mostly unknown. This case underlines that important immune-stimulation can lead to tumor response in a patient previously refractory to all antitumor treatments.

Keywords: acute generalized exanthematous pustulosis; gemcitabine; lung adenocarcinoma; nivolumab.

PubMed Disclaimer

Conflict of interest statement

EGL: BMS (advisory board, honoraria); PM, AC, JF: none.

Figures

FIGURE 1
FIGURE 1
Skin biopsy of patient showing typical histological features of AGEP with subcorneal pustule (1), apoptotic keratinocyte (2) and eosinophil infiltration (3)
FIGURE 2
FIGURE 2
Chest computed tomography (CT) showing the dramatic response observed after one infusion of gemcitabine. (a, b) Baseline CT scan before gemcitabine. (c, d) CT scan after one injection of gemcitabine and AGEP, with a dramatic tumor response
See this image and copyright information in PMC

References

    1. Fukuoka T, Yamamoto Y, Utsunomiya J, Usami E, Kimura M, Yoshimura T, et al. Association between immune‐related dermatologic adverse events and efficacy of pembrolizumab in non‐small cell lung cancer patients. Pharmazie. 2021;76(5):239–42. - PubMed
    1. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune‐related adverse events with nivolumab efficacy in non–small‐cell lung cancer. JAMA Oncol. 2018;4(3):374. - PMC - PubMed
    1. Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, et al. Pooled analyses of immune‐related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. JCO. 2021;39(15_suppl):9002–2. - PMC - PubMed
    1. Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune‐related side effects and efficacy and benefit of immune checkpoint inhibitors – a systematic review and meta‐analysis. Cancer Treat Rev. 2021;92:102134. - PubMed
    1. Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. IJMS. 2016;17(8):1214. - PMC - PubMed

Publication types

MeSH terms